First safety check for hepatitis b drug in vulnerable kidney patients
NCT ID NCT07342881
Summary
This early-stage study is checking how a new hepatitis B drug, pevifoscorvir sodium, is processed by the body in people with reduced kidney function. Researchers will give a single dose to about 30 participants—some with kidney impairment and some with healthy kidneys—and closely monitor drug levels and safety. The goal is to understand if kidney problems affect how the drug works, which is important for future treatment plans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Genesis Clinical Trials
RECRUITINGTampa, Florida, 33603, United States
Contact Email: •••••@•••••
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.